News
AKBLF
31.35
NaN%
--
ALK appoints Tina Abild Olesen as Executive Vice President for Corporate, Portfolio and Product Strategy
Barchart · 09/21 04:00
ALK to present at the Morgan Stanley Global Healthcare Conference in New York
Barchart · 09/11 06:35
ALK-Abelló Earnings Call Highlights Growth Amid Risks
TipRanks · 08/29 00:19
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Barchart · 08/22 05:24
ALK-Abelló A/S reports Q2 results
Seeking Alpha · 08/20 19:25
ALK appoints Jacob Glenting as head of Global R&D
Barchart · 08/20 00:33
Six-month interim report (Q2) 2026 (unaudited)
Barchart · 08/20 00:30
ALK’s tree pollen and house dust mite tablets now recommended by NICE for paediatric treatment in the UK health system
Barchart · 08/14 05:23
Invitation to the presentation of ALK’s first six months (Q2) 2026 results on Thursday, 20 August 2026
Barchart · 08/13 09:06
Market launch of the nasal adrenaline spray, neffy®, for treatment of adults and children with severe allergies in Canada
Barchart · 08/05 06:10
EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis
Barchart · 06/15 02:00
Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap
Barchart · 06/11 02:00
ALK will present data on real world-use of nasal adrenaline and key learnings from 20 years with SLIT-tablets at EAACI 2026
Barchart · 06/04 01:30
Report on transactions with ALK-Abelló A/S B shares and associated securities by managerial staff
Barchart · 06/01 14:20
ALK to present at the Jefferies Global Healthcare Conference in New York
Barchart · 05/29 09:27
ALK-Abello initiated with a Buy at Berenberg
TipRanks · 05/27 08:28
ALK-Abelló Lifts Outlook After Strong Q1 Call
TipRanks · 05/06 00:43
ALK-Abelló A/S reports Q1 results, raises guidance
Seeking Alpha · 05/05 17:06
Three-month interim report (Q1) 2026 (unaudited)
Barchart · 05/04 05:16
More
Webull provides a variety of real-time AKBLF stock news. You can receive the latest news about Alk-Abello A/S through multiple platforms. This information may help you make smarter investment decisions.
About AKBLF
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Company’s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.